FDA Panel OKs Use Of Anemia Drugs, Despite Study

Law360, New York (October 18, 2010, 7:03 PM EDT) -- A U.S. Food and Drug Administration panel said Monday that it was safe for kidney patients who do not require dialysis to continue use of erythropoiesis-stimulating agents made by Johnson & Johnson and Amgen Inc.

The Cardiovascular and Renal Drugs Advisory Committee voted 15-1 against ending use of the ESAs before dialysis and voted 9-5 against cutting doses to patients with hemoglobin levels below 9 grams per deciliter of blood, a representative for Amgen confirmed.

The vote followed a meeting that addressed a recent study finding...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.